Abstract
Development of a water-soluble prodrug of doxorubicin-formaldehyde conjugate, a labile, active metabolite of doxorubicin, is described. The lead compound is the doxorubicin-salicylamide N-Mannich base, N-(2-hydroxybenzamidomethyl)-doxorubicin (doxsaliform), prepared in 72% yield from reaction of salicylamide with doxorubicin in the presence of formaldehyde. Doxsaliform releases doxorubicin-formaldehyde conjugate under physiological conditions with a half-life of 57 min. The stability of the prodrug is augmented both by salt formation in acidic media and by covalent modification of the 2-hydroxyl of the salicylamide moiety. Doxsaliform is 4 fold more active than doxorubicin against MCF-7 breast and PC-3 prostate cancer cell lines and 10 fold more active against the doxorubicin resistant MCF-7 / ADR cell line.
Keywords: doxorubicin, formaldehyde, prodrug, salicylamide, trigger
Letters in Drug Design & Discovery
Title: Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate
Volume: 1 Issue: 3
Author(s): P. S. Cogan, C. R. Fowler, G. C. Post and T. H. Koch
Affiliation:
Keywords: doxorubicin, formaldehyde, prodrug, salicylamide, trigger
Abstract: Development of a water-soluble prodrug of doxorubicin-formaldehyde conjugate, a labile, active metabolite of doxorubicin, is described. The lead compound is the doxorubicin-salicylamide N-Mannich base, N-(2-hydroxybenzamidomethyl)-doxorubicin (doxsaliform), prepared in 72% yield from reaction of salicylamide with doxorubicin in the presence of formaldehyde. Doxsaliform releases doxorubicin-formaldehyde conjugate under physiological conditions with a half-life of 57 min. The stability of the prodrug is augmented both by salt formation in acidic media and by covalent modification of the 2-hydroxyl of the salicylamide moiety. Doxsaliform is 4 fold more active than doxorubicin against MCF-7 breast and PC-3 prostate cancer cell lines and 10 fold more active against the doxorubicin resistant MCF-7 / ADR cell line.
Export Options
About this article
Cite this article as:
Cogan S. P., Fowler R. C., Post C. G. and Koch H. T., Doxsaliform: A Novel N-Mannich Base Prodrug of a Doxorubicin Formaldehyde Conjugate, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043399000
DOI https://dx.doi.org/10.2174/1570180043399000 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Synthesis and Biological Potentials of 5-aryl-N-[4-(trifluoromethyl) phenyl]-1,3,4-oxadiazol-2-amines
Letters in Organic Chemistry WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Predicting Cancer-Related MiRNAs Using Expression Profiles in Tumor Tissue
Current Pharmaceutical Biotechnology Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Bottom-Up Proteomics
Current Analytical Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry An Evidence-Based Review of Medicinal Plants in the Overall Management of Chronic Fatigue
Current Psychiatry Research and Reviews Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews MicroRNAs (miRNAs) in Colorectal Cancer: From Aberrant Expression Towards Therapy
Current Pharmaceutical Design Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Targeting DNA Repair Proteins: A Promising Avenue for Cancer Gene Therapy
Current Gene Therapy Determination of the Percent Composition and Mineral Content of the Leaves of the Insulin Plant (Cissus sicyoides) with the Goal of Including it in the Usual Diet
The Natural Products Journal